Judo Bio Secures $100M Financing to Advance Kidney-Targeted Oligonucleotide Medicines
Key Highlights Judo Bio secures $100M in initial financing for kidney-targeted medicines. Series A co-led by Atlas Venture, TCG, and…
Browsing Tag
Kevin Bitterman
2 posts
GRO Biosciences Secures $60.3M in Series B Financing to Advance Protein Therapeutics
Key Highlights GRO Biosciences raises $60.3M in Series B financing. Funds to advance lead program for refractory gout…